Bagondol, Cherry-ann .
HRN: 00-95-78 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/28/2022
CO-AMOXICLAV 625MG (TAB)
09/28/2022
10/05/2022
ORAL
625mg
BID
S/P NSVD With 2nd Degree Perineal Laceration And Repair
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes